Abstract: A multi-functional pacifier keeps the baby preoccupied while providing entertainment and nutritional benefits. The assembly includes an interchangeable nipple, refillable liquid cartridges for supplying nutritional liquids and nutrients, a rattle toy attached to a clip hook, a detachable teether, and a glow-in-the-dark strap.

Abstract: A dispenser device for dispensing fluids is described. The dispenser can include a reservoir cap that can directly attach to and replace the screw top cap of traditional screw top bottle. The reservoir cap includes an air reservoir that can facilitate movement of the fluid through the device. The reservoir cap is coupled to a dispenser that is configured to receive the fluid from the cap. The dispenser can be detached from the cap and used to directly dispense the fluid.

Abstract: An assembly for delivering medication to a patient has a cartridge loadable with a coiled strip of successively, physically linked medication-containing pouches. The cartridge is inserted into a delivery unit which has an advance mechanism which engages the strip and drives pouches successively out of the cartridge. Pouches are fed successively to an inspection mechanism and a separation station. At the inspection station indicia on successive pouches representing a medication schedule are inspected and compared and validated against a separately stored medication schedule recorded at the time the medication is packaged in the cartridge. A separation mechanism mounted at the separation station is used to separate a pouch at the leading end of the strip from the adjacent pouches. At a pouch exit, separated pouches are routed to a delivery zone.

Abstract: A method for providing a singling device of a storage and dispensing container for drug portions is provided. A singling device is adapted to a specific drug portion based on the measurement of the drug portion. The measurement is obtained by generating at least one image of a to-be-measured drug portion by a detection device and using image analysis to process the at least one image. Drug information for the specific drug portion is determined, the drug information including at least the dimensions of the specific drug portion. Based on the determined drug information, a singling device fitting the drug portion to be singularized is identified and provided for use in the storage and dispensing container. A system for identifying a singling device is also provided.

Abstract: The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.

Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Abstract: The invention relates to combined liposuction methods and can be used in surgical interventions to remove local fat deposits in the lower third of the face and neck. The method includes a preoperative examination of the patient when one or more areas of the lower third of the face and neck of the patient are designated as liposuction areas constituting the operative field. The contour boundaries of the operative field and at least one operative access point are determined. Uniform infiltration anesthesia of the adipose tissue to be removed in the liposuction areas is performed. From a Nd:YAG laser radiation source with a wavelength of 1064 nm, a Nd:YAG laser radiation with a wavelength of 1064 nm in a pulsed mode with a frequency of 50 Hz, with a pulse duration of 300 ?s and a power of the predetermined value is supplied directly to the adipose tissue to be removed.

Abstract: The present disclosure provides the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in treating a neurological disease associated with repeat expansions and/or RAN protein accumulation, reducing the level of one or more repeat associated non-ATG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and/or biological sample. Also provided is the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in inhibiting RAN protein translation in a subject and in a biological sample (e.g., cells, tissue). Also provided in the present disclosure are pharmaceutical compositions, Skits, and uses of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) for treating diseases associated with repeat expansions.

Abstract: Methods of treating obesity include administering to a subject in need thereof an effective amount of a therapeutic agent capable of reversing an inhibition of a Na/K-ATPase in a small intestine of a subject, such as a basolateral membrane Na/K-ATPase. Administering the therapeutic agent can further decrease an amount of glucose transport and/or decrease an amount of salt absorption in the small intestine of the subject to thereby treat the obesity. Methods for screening for a compound useful for treating obesity include contacting a small intestine cell with an effective amount of a test compound, and detecting whether an activity level of a Na/K-ATPase in the small intestine cell is increased in the presence of the test compound. The test compound is then identified as a compound useful for the treatment of obesity if the activity level of the Na/K-ATPase is increased in the presence of the test compound.

Abstract: Provided is a composition for the prevention and treatment of one or more cancers selected from the group consisting of breast cancer, liver cancer, and gastric cancer, the composition comprising selenopsammaplin A as active ingredients. The selenopsammaplin A and derivatives thereof of the present invention have been confirmed to exhibit excellent anticancer activity against breast cancer, liver cancer, and gastric cancer cells, and exhibit not only a strong effect of suppressing breast cancer growth compared to existing psammaplin A but also an excellent effect of suppressing the metastasis of breast cancer cells, and thus the selenopsammaplin A and derivatives thereof are expected to be effectively usable as a pharmaceutical composition for the prevention and treatment of breast cancer, liver cancer, and/or gastric cancer, and for the suppression of breast cancer metastasis.

Abstract: Systems and methods for treating a fibrous mass, which is comprised of a Morton's neuroma, are disclosed. In one exemplary implementation, a method may comprise identifying a location of the fibrous mass and non-surgically delivering electromagnetic energy to the fibrous mass. Embodiments may include delivering the energy via a Nd:Yag laser at various specified parameters, such as duration, pulse count, and tissue depth, among others.

Abstract: This invention discloses uses for sulindac in preparing anti-lung cancer products. This invention provides uses for sulindac in the preparation of products to treat lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug sulindac, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that sulindac has a new use as an anti-lung cancer medication, thus achieving a new purpose for an old drug.

Abstract: The present invention provides a gel patch having a paste layer on a support, wherein the paste layer comprising ketoprofen or a pharmaceutically acceptable salt thereof, propylene glycol, 1-menthol, and water, wherein the mass of propylene glycol in the paste layer is 3-fold the mass of ketoprofen or less, and wherein the content of 1-menthol based on a total mass of the paste layer is 0.1 to 0.5 mass %.

Abstract: Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.

Abstract: The present invention relates to PD-0184264 for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza vims infection or a viral or bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial or viral infection alone.

Abstract: Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared to treatments comprising dimethyl fumarate (e.g., TECFIDERA®). In particular, described herein are oral pharmaceutical compositions comprising monomethyl fumarate in a liquid vehicle that have reduced gastrointestinal side effects.

Abstract: The present invention relates to an oral tablet for delivery of cannabinoids to mucosal surfaces comprising a population of particles and one or more cannabinoids, the population of particles comprising a) directly compressible (DC) sugar alcohol particles and b) non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.

Abstract: An oil-based formulation comprising a cannabinoid and pico size carbon particles. The formulation is suitable for administration to a patient having a medical condition requiring the use of cannabinoid.

Abstract: Provided herein are methods of treatment, including methods of treating subjects having or at risk of having or having a viral infection, and specifically a SARS-CoV-2 viral infection. The methods provided include the administration of 4-methylumbelliferone (4-MU), palmitoylethanolamide (PEA), resveratrol, fisetin, H2, nebulized hyaluronidase or combinations thereof. Also provided herein are a respiratory assistance device, methods of generating a customized respiratory assistance device, methods of treating a coronavirus infection, and methods of inhibiting a coronavirus infectivity, virulence and/or spread.

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-?B signaling pathway activation and COX-2 expression, activation of PPAR-? expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.

Abstract: The present invention provides anti-HBV compounds, pharmaceutically acceptable compounds or stereoisomers thereof, and preparation methods and uses for treating, eradicating or inhibiting HBV infection or for alleviating liver injury caused by HBV infection, and so on.

Abstract: Compositions comprising melatonin or derivatives thereof for administration to the epithelium of the lower airway to protect against lung damage due to chest irradiation and/or cytotoxic chemotherapy are provided.

Abstract: The subject invention describes the use of dopamine agonists with affinity for the dopamine D2, D3, or D4 receptors (the D2 family) for treatment of hot flashes, regardless of their being caused by natural aging in women or medical/surgical intervention of the HPG axis in either sex. The D2 family of dopamine receptors is most responsive to D2 agonist molecules, but also responsive to multiple other molecules that directly or indirectly utilize this pathway. Alpha-2-adrenergic agonists act synergistically to further reduce the frequency and severity of hot flashes and prolong the duration of dosing effectiveness. The combination of a D2 family dopamine agonist and alpha-2-adrenergic agonist, as well as additional molecules that can utilize the D2 receptor family pathway through formation of heterodimers, permits a multitude of molecules of varying efficacy for the treatment of hot flashes in either women or men.

Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.

Abstract: The present disclosure related to methods of treating pruritus in a subject by topically administering detomidine, or a pharmaceutically acceptable salt thereof, to the subject.

Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.

Abstract: The present invention provides novel methods for enhancing muscle function in a mammal, the method includes administration to the mammal of a composition comprising therapeutically effective amount of dihydroberberine (DHB) or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof. The present invention also provides a composition including therapeutically effective amount of dihydroberberine (DHB) or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, for enhancing muscle function. In addition, the present invention provides methods for preparing any compositions disclosed herein.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

Abstract: The present invention is related to new pyrrole derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to pyrrole derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

Abstract: Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.

Abstract: The present disclosure provides a patch preparation having features that prevent accidental use. In some embodiments, a patch preparation containing a plaster on a support, wherein the plaster comprises a solvent that is a combination of ethyl acetate and n-heptane. The patch preparation can lose its adhesion after the plaster is exposed to air and at least some of the solvent has evaporated, or if the patch is removed from the skin. This feature prevent the used patch from being applied to the skin again, and can prevent accidental use. A method of forming a patch preparation is also disclosed.

Abstract: Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Abstract: An experimental model using pazopanib-induced cardiotoxicity is provided. The experimental model using pazopanib-induced cardiotoxicity includes administering an effective dosing regimen of pazopanib to induce a cardiotoxicity in a subject. The induced cardiotoxicity may include hypertension, arrhythmia, or cardiac toxicity. The dosing regimen may include administering a single dose or administering one or more daily doses of pazopanib. The dosing regiment may continue for a period of time between at least 10 and at least 30 days. The dose of pazopanib may be between 25 and 350 mg/kg.

Abstract: Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication.

Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.

Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.

Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.

Abstract: In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes, bone loss, and cancer, using a compound of Formula I.

Abstract: The disclosure includes compounds of Formula (A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

Abstract: Described herein are nasal pharmaceutical compositions comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located inside pores of the porous excipient, and wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions.

Abstract: Disclosed herein are methods and compositions useful in reducing inflammation, reducing inflammatory exudates, enhancing epithelial tissue generation or regeneration, and/or reducing mean pulmonary artery pressure in the lungs of a subject in need thereof. In particular, the compositions comprise vitamin D, an analog, or metabolite thereof, and the methods include administering the composition to a subject in need thereof. In some embodiments, the subject is suffering from an infection, such as a viral infection, which affects the lungs. In some embodiments, the viral infection comprises SARS-CoV-2.